摘要:
The present invention relates to pyridopyrazinone derivatives of formula (I), wherein X, Y, Z1 W, A and R1 are as defined in claim 1, as insulin secretion stimulators. The invention also relates to the preparation and use of these pyridopyrazinone derivatives for the prophylaxis and/or treatment of diabetes and pathologies associated.
摘要:
The invention relates to compounds of the general formula (I), in which R1, R2, R3, R4, R5, R6 and X are as defined in Claim 1. These compounds can be used in the treatment of pathologies associated with insulin resistance syndrome.
摘要:
The invention relates to compounds of the general formula (I) in which R1, R2, R3, R4, R5, R6 and X are as defined in Claim 1. These compounds can be used in the treatment of pathologies associated with insulin resistance syndrome.
摘要:
The invention relates to the field of chemistry and more particularly to that of therapeutic chemistry. The invention more precisely features novel 5-phenoxyalkyl 2,4-thiazolidinediketones of general formula (I): in which A represents one linear or branched alkylene group comprising 2 to 16 carbon atoms D represents one monocyclic, bycyclic or tricyclic, homocarbonaceous or heterocarbonaceous aromatic structure capable of enclosing one or several heteroatoms X represents the aromatic structure substituent and is as defined in claim 1 n is one integer ranging from 1 to 3 with the restriction that if A represents one butyl radical, (a) does not represent the 4-chlorophenyl group. The invention also disclosed tautomer, enantiomer, diastereoisomer and epimer forms of general formula (I) compounds, in free or salified form. The invention also discloses methods for obtaining general formula (I) compounds, their use as antidiabetic agents, and in the insulin resistance metabolic syndrome, as well as in the pharmaceutical compositions that contain general formula (I) compounds.
摘要:
The present invention relates to quinoxalinone derivatives of formula (I), wherein R1, R2, R3, R4, R5 and R6 are as defined in claim 1, as insulin secretion stimulators. The invention also relates to the preparation and use of these quinoxalinone derivatives for the prophylaxis and/or treatment of diabetes and pathologies associated. Other preferred compounds are compounds of general formula (I), wherein R1, R2, R3, R4, R5 and R6 can be optionally substituted by one or more groups selected from Z.
摘要:
The invention relates to compounds of the general formula (I), in which R1, R2, R3, R4, R5, R6 and X are as defined in Claim 1. These compounds can be used in the treatment of pathologies associated with insulin resistance syndrome.